These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 553398)

  • 21. Pergolide and lisuride for Parkinson's disease.
    Lieberman AN; Leibowitz M; Neophytides A; Kupersmith M; Mehl S; Kleinberg D; Serby M; Goldstein M
    Lancet; 1979 Nov; 2(8152):1129-30. PubMed ID: 91856
    [No Abstract]   [Full Text] [Related]  

  • 22. Mesulergine and pergolide in previously untreated Parkinson's disease.
    Wright A; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1987 Apr; 50(4):482-4. PubMed ID: 3585362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression of REM rebound by Pergolide.
    Askenasy JJ; Yahr MD
    J Neural Transm; 1984; 59(2):151-9. PubMed ID: 6726217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients.
    Schneider E; Hubener K; Fischer PA
    Adv Neurol; 1984; 40():527-9. PubMed ID: 6695631
    [No Abstract]   [Full Text] [Related]  

  • 25. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
    Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
    Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
    Rascol O; Fabre N; Teräväinen H; Poewe W; Lücking C; Rinne U; Dupont E; Hirt D; Hoyer M; Lataste X
    Clin Neuropharmacol; 1990 Aug; 13(4):303-11. PubMed ID: 2208182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pergolide mesylate: lack of cardiac toxicity in patients with cardiac disease.
    Tanner CM; Chhablani R; Goetz CG; Klawans HL
    Neurology; 1985 Jun; 35(6):918-21. PubMed ID: 3889707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of advanced Parkinson disease with pergolide.
    Lieberman A; Goldstein M; Leibowitz M; Neophytides A; Kupersmith M; Pact V; Kleinberg D
    Neurology; 1981 Jun; 31(6):675-82. PubMed ID: 7195484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM; Houeto JL
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesulergine (CU32-085) in the treatment of Parkinson's disease.
    Pfeiffer RF; Wilken K; Glaeske C
    Ann Neurol; 1985 Apr; 17(4):334-6. PubMed ID: 3890700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term experience with pergolide therapy of advanced parkinsonism.
    Kurlan R; Miller C; Levy R; Macik B; Hamill R; Shoulson I
    Neurology; 1985 May; 35(5):738-42. PubMed ID: 3887213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pergolide therapy for Parkinson's disease: neurobehavioral changes.
    Stern Y; Mayeux R; Ilson J; Fahn S; Cote L
    Neurology; 1984 Feb; 34(2):201-4. PubMed ID: 6538009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pergolide in late-stage Parkinson disease.
    Lang AE; Quinn N; Brincat S; Marsden CD; Parkes JD
    Ann Neurol; 1982 Sep; 12(3):243-7. PubMed ID: 6753730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parallel double-blind study of pergolide in Parkinson's disease.
    Jankovic J; Orman J
    Adv Neurol; 1987; 45():551-4. PubMed ID: 3548265
    [No Abstract]   [Full Text] [Related]  

  • 36. The effects of pergolide on the cardiovascular system of 40 patients with Parkinson's disease.
    Leibowitz M; Lieberman AN; Neophytides A; Gopinathan G; Goldstein M
    Adv Neurol; 1983; 37():121-30. PubMed ID: 6858770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Valvular heart disease in a patient with Parkinson's disease treated with a low daily dose and a low cumulative dose of pergolide.
    Chung EJ; Yoon WT; Kim JY; Lee WY
    Mov Disord; 2006 Apr; 21(4):586-7. PubMed ID: 16482572
    [No Abstract]   [Full Text] [Related]  

  • 38. Pergolide-induced retroperitoneal fibrosis.
    Mondal BK; Suri S
    Int J Clin Pract; 2000; 54(6):403. PubMed ID: 11092116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of pergolide on the kinetics of the dopamine receptors in the corpus striatum of the rat].
    Jiang DH
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):209-13. PubMed ID: 4075909
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of Parkinson's disease. From theory to practice.
    Ahlskog JE
    Postgrad Med; 1994 Apr; 95(5):52-4, 57-8, 61-4 passim. PubMed ID: 8153048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.